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Other than lung transplantation (LT), no speciﬁc therapies exist for end-stage lung disease resulting from
hematopoietic stem cell transplantation (HCT)-related complications, such as bronchiolitis obliterans syn-
drome (BOS). We report the indications and outcomes in patients who underwent LT after HCT for hema-
tologic disease from a retrospective case series at our institution and a review of the medical literature. We
identiﬁed a total of 70 cases of LT after HCT, including 9 allogeneic HCT recipients from our institution who
underwent LT between 1990 and 2010. In our cohort, the median age was 16 years (range, 10 to 35 years) at
the time of HCT and 34 years (range, 17 to 44 years) at the time of LT, with a median interval between HCT and
LT of 10 years (range, 2.9 to 27 years). Indications for LT-included pulmonary ﬁbrosis (n ¼ 4), BOS (n ¼ 3),
interstitial pneumonitis related to graft-versus-host disease (GVHD) (n ¼ 1), and primary pulmonary hy-
pertension (n ¼ 1). Median survival was 49 months (range, 2 weeks to 87 months), and 1 patient remains
alive at more than 3 years after LT. Survival at 1 year and 5 years after LT was 89% and 37%, respectively. In the
medical literature between 1992 and July 2013, we identiﬁed 20 articles describing 61 cases of LT after HCT
from various centers in the United States, Europe, and Asia. Twenty-six of the 61 cases (43%) involved patients
age<18 years at the time of LT. BOS and GVHD of the lung were cited as the indication for LT in the majority of
cases (80%; n ¼ 49), followed by pulmonary ﬁbrosis and interstitial lung disease (20%; n ¼ 12). In publications
reporting 3 or more cases with a follow-up interval ranging from the immediate postoperative period to 16
years, the survival rate was 71% (39 of 55). Most deaths were attributed to long-term complications of the
lung allograft, including infections and BOS. Two deaths were related to recurrent or relapsed hematologic
malignancy. LT can prolong survival in some patients who suffer from end-stage pulmonary complications
after HCT. Patient factors that likely improve the chances of a good long-term outcome include young age, at
least 2 years post-HCT free of relapse from the original hematologic malignancy, and lack of other end-organ
dysfunction or manifestations of chronic GVHD that require treatment with immunosuppressive agents.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Survival after allogeneic hematopoietic stem cell trans-
plantation (HCT) has improved over the course of several
decades, owing to the development of less-toxic pre-
transplantation conditioning regimens, more effective pro-
phylaxis of acute graft-versus-host disease (GVHD), improved
infection control, and advances in supportive care in the post-
transplantation period [1]. Accordingly, more individuals are
living longer after HCT.
Long-term survival still comes at a cost, however. Up to
26% of allogeneic transplant recipients develop late-onset
noninfectious pulmonary complications, including bron-
chiolitis obliterans syndrome (BOS). BOS, considered part of
the spectrum of chronic GVHD (cGVHD) manifestations [2],
affects 5.5% of allogeneic transplant recipients and 14% of
those who develop cGVHD [3]. In addition to BOS, allogeneic
HCT recipients may suffer from other manifestations ofdgments on page 1174.
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monia, or from pulmonary ﬁbrosis resulting from treatment
for the underlying malignancy or the pretransplantation
regimen. These noninfectious pulmonary complications of
allogeneic HCT signiﬁcantly compromise quality of life and
contribute to nonrelapse mortality after cure of the patient’s
original hematologic disease.
Lung transplantation (LT) is now a well-established
therapy for many pulmonary conditionsdchronic obstruc-
tive pulmonary disease, cystic ﬁbrosis, idiopathic pulmonary
ﬁbrosisdwhen all other forms of medical and surgical
therapy have failed. Through June 2012, 45,000 LTs have
been reported worldwide [4]. Similar to some of these pul-
monary conditions, no speciﬁc disease-modifying therapies
exist for BOS related to cGVHD or toxicity-related interstitial
lung disease. Thus, it seems reasonable to consider LT as an
option for BOS or other pulmonary complications when end-
organ damage has resulted in severe compromise of activ-
ities of daily living and appears to be inexorably leading to
the patient’s early demise.
The ﬁrst case of LT after bonemarrow transplantationwas
reported in 1992 [5], and since then, sporadic case reports
and case series have been published documenting the use ofTransplantation.
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cations of HCT. Even so, LT after HCT is rare, and the outcomes
of LT in this population have not been well described.
In this report, we present our institutional experience
with outcomes of LT after HCT and review the experience
reported in the literature. We also review the current con-
siderations of LT and propose recommendations for the
selection of appropriate candidates for LT from this popula-
tion of patients.
METHODS
Case Series
We performed a retrospective chart review of cases of LT performed
after HCT at Fred Hutchinson Cancer Research Center (FHCRC). Cases of LT
after HCT were identiﬁed by physicians of the Long-Term Follow-Up (LTFU)
program and pulmonary consultative services. The data used in this study
rely on documentation in the medical record generated by the LTFU, which
provides lifelong telemedicine to all patients undergoing transplantation
at FHCRC and to their physicians in addition to onsite consultation, as
described previously [6]. All patients who underwent allogeneic HCT at
FHCRC between January 1971 and December 2011 with proven documen-
tation of LT from the LTFU database are included in this report. This time
frame for the cohort was selected to ensure adequate follow-up time.
Follow-up for identiﬁed LTcases was date of recorded death or December 31,
2013, whichever came ﬁrst. Clinical information was extracted by chart and
database review. Written consent for the use of medical records for research
was obtained from patients before transplantation. This study was approved
by the FHCRC Institutional Review Board.
Literature Review
We performed a computerized search of the MEDLINE and Scopus da-
tabases using the key terms “lung transplantation,” “after,” “bone marrow
transplantation,” “hematopoietic cell transplantation,” and “bronchiolitis
obliterans” between January 1991 and July 31, 2013. We also reviewed
reference lists of included studies for additional publications. All English
language publications describing a case of LT after HCT were included.
Publications were reviewed individually, and speciﬁc parameters and out-
comes were collated.
Statistical Analysis
Survival analysis was performed with the Kaplan-Meier method.Table 1
Characteristics of the Case Series Cohort, FHCRC
Case Sex Year
of LT
Age at
HCT, yr
Age at
LT, yr
Indication
for HCT
HCT Source Time
from HCT
to LT, mo
Indic
1 Female 1990 19/23 25 ALL BM (2),
related
35 Pulm
to ch
2 Female 1991 11 17 AML BM, related 66 Inter
to ra
vers
pneu
3 Male 1995 16 40 Aplastic
anemia
BM, related 292 BOS
4 Female 1997 10 24 ALL BM, related 174 BOS
5 Male 2000 35 44 AML BM, related 123* Inter
inter
6 Female 2002 32 41 CML BM,
unrelated
113 Prim
hype
to m
7 Female 2004 10 37 AML BM, related 326 Pulm
chem
radia
8 Male 2009 16 34 ALL PBSC,
unrelated
204 Pulm
to ch
radia
9 Male 2010 28 32 ALL PBSC,
unrelated
45 BOS
LT, lung transplantation; HCT, hematopoietic stem cell transplantation; BM, bonem
AML, acute myelogenous leukemia; CML, chronic myelogenous leukemia; GVHD
cytomegalovirus; NA, not applicable.RESULTS
Patient Characteristics and Outcomes after LT
We identiﬁed 9 individuals out of 10,548 recipients of
allogeneic HCT performed in Seattle between 1971 and 2011
who subsequently underwent LT between 1990 and 2010
(Table 1). The median age at HCT was 16 years (range, 10 to
35 years). Indications for HCT included acute leukemia
(n ¼ 7), chronic myelogenous leukemia (n ¼ 1), and aplastic
anemia (n ¼ 1). Six patients underwent HCT from an HLA-
matched related donor, and the other 3 did so from an
HLA-matched unrelated donor. The median age at LT was
34 years (range, 17 to 44 years), with a median interval of
10 years (range, 2.9 to 27 years) from HCT to LT. Indications
for LT included interstitial lung disease (ie, interstitial
ﬁbrosis, pulmonary ﬁbrosis, interstitial pneumonitis) in 5
patients, BOS in 3 patients, and primary pulmonary arterial
hypertension in 1 patient. Four patients underwent single LT,
and 5 underwent bilateral LT; all transplanted lungs were
from cadaver donors. Owing to a wide geographic distribu-
tion as well as variability in LT selection criteria, the patients
underwent LT at several institutions. Data regarding pul-
monary function tests, immunosuppressivemedications, and
the presence of active cGVHD were limited.
Of the 9 patients who underwent LT over a period of >20
years, 1 patient remains alive more than 3 years after his
bilateral LT and 7 years after his HCT. Median survival after LT
was 49 months in the remaining patients (Figure 1). One-
year survival of this cohort was 89%, and 5-year survival
was 37%. Most of the deaths were related to lung allograft
rejection or infectious complications (Table 1). One patient
died at 2 weeks after LT; the cause was not reported.
Literature Review
Excluding our present cohort, a total of 61 cases of LT after
HCT were reported in 20 published manuscripts in the En-
glish language medical literature between 1992 and 2013ation for LT Type
of LT
Survival
after LT
Cause of Death
onary ﬁbrosis due
emotherapy
Single 6 yr, 2 mo Chronic rejection/CMV
pneumonitis
stitial ﬁbrosis due
diation therapy,
us interstitial
monitis due to GVHD
Single 4 yr, 6 mo Respiratory failure/
progressive pneumonia
due to stenotic
complication of LT
Bilateral 3 yr, 8 mo Chronic graft rejection
(bronchiolitis obliterans),
bilateral bronchial stenosis,
pseudomonas infection
Bilateral 2 yr, 7 mo Brain damage due to
cardiac/respiratory arrest
stitial pneumonitis/
stitial ﬁbrosis
Single 2 wk Immediate post-LT;
immediate cause unknown
ary pulmonary
rtension not related
alignancy or HCT
Single 7 yr, 3 mo Respiratory failure/viral
pneumonia in transplanted
lung; recurrence of CML
onary ﬁbrosis due to
otherapy and
tion therapy
Bilateral 6 yr, 1 mo Septic shock, pulmonary
fungal infection
onary ﬁbrosis due
emotherapy and
tion therapy
Bilateral 2 yr, 6 mo Chronic graft rejection/
primary graft dysfunction
Bilateral >3 yr NA
arrow; PBSC, peripheral blood stem cells; ALL, acute lymphoblastic leukemia;
, graft-versus-host disease; BOS, bronchiolitis obliterans syndrome; CMV,
Figure 1. Survival of LT after HCT recipients from the FHCRC cohort (n ¼ 9).
The tick mark denotes a patient who was alive at 41 months post-LT as of last
contact in December 2013.
G.-S. Cheng et al. / Biol Blood Marrow Transplant 20 (2014) 1169e1175 1171[5,7-25] (Table 2). Twelve single case reports have been
published, 1 of which was reported in 2 different publica-
tions [9,10]. Five cases were reported twice as part of a larger
case series [8,11,12,14,19]. These cases originated from mul-
tiple centers in the United States, Europe (United Kingdom,
Austria, Denmark, and the Nordic nations), and Asia (Japan,
Hong Kong, and Korea).
Of note, the ﬁrst known case of LT after HCT reported in
Chest in 1992 was a 25-year-old woman who underwent her
ﬁrst related-donor allogeneic bonemarrow transplantation at
Fred Hutchinson Cancer Research Center in 1984 for acute
lymphocytic leukemia [5]. She underwent a second bone
marrow transplantation 4 years later for disease relapse. She
developed progressive pulmonary ﬁbrosis leading to respira-
tory failure, and underwent a single LT at another institution
in1990, 2 years afterher secondbonemarrow transplantation.
This patient is included in our analysis of outcomes.
Twenty-six of the 61 patients in the literature cohort
(43%) were age <18 years at the time of LT. The cohort
included 12 living-donor lobar LT (LDLLT) recipients, 6 of
whom were age 18 years at the time of transplantation.
Most of the LDLLTs were performed in Japan. At least 33
patients underwent bilateral cadaveric LT, and 6 patients
underwent single cadaveric LT. Yousef et al. [23] did not
report the types of LTs performed in their multicenter series
of 11 pediatric HCT recipients.
The median interval between HCT and LT was 5 years
(range, 0.67 to 25 years) in 15 publications reporting this
information, and the median age at the time of LT was 24.5
years (range, 4 to 59 years) in 18 publications. The youngest
patient was a 4-year-old child who underwent LDLLT from
his mother at 3 years after undergoing peripheral blood stem
cell transplantation for myelomonocytic leukemia, for which
the mother was the donor as well [16].
For the 11 single case reports, the median length of
follow-up was 14 months (range, 1 to 38 months) at the time
of this writing, which included 1 death at 9 months. Among
the remaining publications that analyzed 3 or more cases, for
a total of 55 cases, the aggregate survival rate at the time of
publication was 71% (n ¼ 39), with the majority of cases
followed for 2 years (range, immediate postoperative
period to 16 years) (Table 2). Most deaths were attributed to
long-term complications of the lung allograft, speciﬁcally
infectious complications from chronic immunosuppression
or BOS. Only 1 reported death was due to recurrent hema-
tologic malignancy.DISCUSSION
Chronic pulmonary disease that arises as a complication of
HCT presents a challenging and frustrating problem, particu-
larly when the patient is young and essentially cured of a
previously life-threatening condition. Prognosis after a diag-
nosis of BOS is associatedwith a 1.6-fold increase in the risk of
mortality compared with HCT recipients without BOS [3], and
the reported 5-year survival rate is only 13% [26]. Aswith end-
stage lung disease from other causes, therapeutic options for
pulmonaryGVHDand regimen-related pulmonaryﬁbrosis are
limited to palliation once chronic respiratory failure ensues. LT
improves quality of life and survival in patients with various
pulmonary conditions refractory tomaximalmedical therapy;
however, limited information is available regarding the in-
dications and outcomes of LTafterHCT to help guide clinicians
in exploring this therapeutic option.
Here we report 9 recipients of allogeneic HCT performed
at FHCRC who received LT for end-stage lung disease over a
20-year time frame, and summarize 61 cases published in the
medical literature. This aggregate of 70 cases worldwide
suggests that LT may be an increasingly acceptable option in
select patients. The apparent increase in number of publica-
tions in the past 5 years describing LT after HCT likely reﬂect
the rise in the number of HCT recipientswho are living longer,
the increasing number of LT programs worldwide, as well as
cumulative accrual of these LT after HCT recipients over time.
Based on the growing list of indications for HCT, as well as
the increasing number of long-term HCT survivors, we can
expect to see more HCT recipients who experience late-onset
pulmonary complications. The number of allogeneic HCTs
performed worldwide increased from 2006 to 2008 to
exceed 20,000 annually [27]. One-year survival approached
60% in 2010 [28] and continues to improve. Approximately
30% to 50% of these long-term survivors will develop cGVHD
[29], and 14% will develop BOS [3]. Patients with BOS, along
with patients with other treatment-related pulmonary
complications, such as interstitial lung disease, yield a sub-
stantial population for whom LTcould be considered. In 2011,
3747 LTs were performed worldwide (26% single and 74%
bilateral); 97% of recipients were age >17 years [4]. The use
of LT is limited by donor organ availability as well as recipient
characteristics, which in the setting of HCTmay include other
morbidities related to the previous graft. Because of the
scarcity of donor lungs, this life-saving procedure is neces-
sarily limited to patients with the most urgent need for
intervention with factors that confer a high likelihood of a
good outcome.
Outcomes
Given the heterogeneity in age, transplant type, era of
transplantation, and limited data available for the 70 patients
identiﬁed in our study, a statistically meaningful comparison
of long-term outcomes for LT after HCT with LT overall is not
possible. However, we can conclude that long-term survival
with a good quality of life is possible in some patients, as
observed in our cohort as well as in the reviewed literature.
In our cohort, the 1-year survival after LT of 89% is com-
parable to the 2010 national 1-year survival of 87% reported
by the Organ Procurement and Transplantation Network/
Scientiﬁc Registry of Transplant Recipients (OPTN/SRTR)
[30]. This organization administers the uniﬁed national
waiting list for solid organ transplant candidates, and
maintains data from every organ donation and transplant
event occurring in the United States since 1987. Our cohort’s
37% 5-year survival is comparable to the 39% survival rate of
Table 2
Publications Reporting Cases of LT after HCT
Reference Year of
Publication
First Author Journal Location of LT n Age at HCT, yr Age at LT, yr Indication for LT Follow-Up Outcome at
Publication (n 3)
5 1992 Calhoon Chest San Antonio, Texas 1 19/23 25 PF 9 mo
7 1994 Gascoigne Chest England 1 Unknown 27 BOS 9 mo
8 1994 Boas Chest University of Pittsburgh
Children’s Hospital
1 5 14 GVHD of lung
(BOS and ﬁbrosis)
15 mo
9 1995 Svendsen Eur Resp J Denmark 1 5 11 GVHD of lung 14 mo
10 1999 Svendsen J Heart Lung Transplant Denmark 1[9]* 5 11 GVHD of lung 14 mo
11 2001 Heath Transplantation Pittsburgh, Philadelphia 4y 3-16 30, 13.5, 6, 14.5 GVHD of lung (3), PF (1) 3-6 yr 2 deaths at 3 and 6 yr,
2 alive at 5.5-6 yr
12 2001 Rabitsch Transplantation Austria 1 37 38 BOS 23 mo
13 2003 Pechet J Heart Lung Transplant St Louis Children’s Hospital 6 Not reported 12.4 (mean) BOS (3), PF (3) >48 mo 2/3 (67%) survival
14 2005 Sano Ann Thoracic Surg Okayama, Japan 1 29 34 BOS 38 mo
15 2007 Okumura Int J Hematol Kanazawa, Japan 1 17 24 BOS 30 mo
16 2007 Shiraishi J Thorac Cardiovasc Surg Fukuoka City, Japan 1 1 4 BOS Immediate
17 2007 Au J Heart Lung Transplant Hong Kong 1 Not reported 29 BOS 6 mo
18 2008 Yamane Transplantation Okayama, Japan 7[14]z Not reported 6, 13, 23, 24, 27, 29, 45 BOS (6), PF (1) 38 mo 5/7 (71%) survival
19 2009 Oshima Int J Hematol Okayama, Japan 1[18]x 8 13 BOS 30 mo
20 2010 Redel-Montero Transplant Proc Cordoba, Spain 3 8-27 36, 36, 34 BOS 9 mo to 8 yr 100% survival
21 2012 Whitson Clin Transplant University of Minnesota 4 6-53 40, 20, 30, 59 GVHD of lung (2), PF (2) 19-119 mo 100% survival
22 2012 Kim Yonsei Med J Seoul, Korea 1 Not reported 21 BOS 10 mo
23 2012 Yousef Pediatr Transplant Multicenter
(US, Switzerland, Austria)
11[11]k 1-12 15 (median) BOS (5), GVHD (3), PF (3) 19 mo (median) 7/11 (64%) survival
24 2013 Vogl Transplantation Austria 7[12]{ 24 (median) Not reported; all >18 BOS (7) 1 mo to 16 yr 3/7 (43%) survival
25 2013 Holm Bone Marrow Transplant Nordic countries (Finland,
Norway, Sweden, Denmark)
13 24 (median) 34 (median) BOS (13) 4.2 yr (median) 1-yr survival, 90%;
3-yr survival, 78%;
5-year survival, 75%
PF indicates pulmonary ﬁbrosis.
* Reported in [9].
y Reported in [8].
z One case reported in [14].
x Reported in [18].
k One case reported in [11].
{ One case reported in [12].
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reported in 2006, the last year for which data are available
(Figure 2) [30]. Our cohort underwent LT between 1990 and
2010, during which long-term outcomes for LT of all types of
recipients steadily improved [31].
LT, like HCT, carries signiﬁcant associated risks and com-
plications. In our review series, BOS was the most common
indication for LT as well as the most common post-LT
complication and cause of death or indication for retrans-
plantation. BOS is the leading cause of death beyond the ﬁrst
year post-LT, andnearly 50% of recipients develop BOS by year
5 post-LT [32]. Aswith BOS after HCT, few therapeutic options
are available for progressive BOS after LT. Immunosuppres-
sion after LT is lifelong, conferring the risk of opportunistic
infections,malignancy, and systemic side effects. Some40% of
deaths within the ﬁrst year after LT, and 20% of deaths after
the ﬁrst year, are due to infection, andmore than 10% of long-
term deaths are due to malignancy [4].
Recipients of LT after HCT tend to be younger than LT
recipients overall. More than one-third of the cases in this
review were pediatric patients at the time of LT. In contrast,
<3% of LT recipients are age <18 years; most of these are
patientswith cysticﬁbrosis age 12 to 17 years [33]. In addition
to the pediatric cases reported, most adult cases were
younger at the time of LT than the average LT candidate,
which also reﬂects the younger age of HCT recipients histor-
ically. Themedian age at LTof our FHCRC cohortwas 34 years;
worldwide, it was 56 in 2011. In the most recent series re-
ported by Holm et al. [34], the median age at HCT was 24
years, with a median time to LT of 8.2 years. In adult patients,
older agehas been associatedwith increased risk ofmortality.
Twelve cases of LDLLT have been reported among HCT
recipients, ranging in age from4 to 45 years. All but 1 of these
procedures were performed in Japan. LDLLT is an uncommon
procedure. Obvious advantages of this technique include
eliminating the time factor of waiting for a cadaveric donor.
Whereas chronic immunosuppression could be avoided if the
living lobar donor were also the donor of the previous HCT,
functional outcome after a single LT likely would be subop-
timal. In 3 cases, a pediatric patient received a lung allograft
from themother, whowas also the donor of the previous HCT
[9,10,16,19]. Chimerism from the HCT induced tolerance of
the lung allograft, obviating the need for chronic immuno-
suppression. The tolerance induced by chimerism also has
been reported in renal transplantation after HCT [35,36].Figure 2. One-year and 5-year survival of the FHCRC cohort (n ¼ 9) compared
with national outcomes. Survival outcome is shown for all LTs performed in
the United States for the year shown on the bar graph. Survival data obtained
from the 2011 Annual Data Report published by OPTN/SRTR, accessed online
January 31, 2014.From a practical standpoint, LDLLT may be challenging
because it requires more than 1 donor unless the recipient is
a small child. Since the implementation of the Lung Alloca-
tion Score in the United States in 2005, which prioritizes the
waiting list by need rather than by time of listing, the time to
obtaining a suitable cadaveric allograft has declined signiﬁ-
cantly, thus obviating the need for LDLLT [31]. Only 12 LDLLT
procedures have been performed in the United States since
2005 (based on OPTN data as of February 21, 2014 at http://
optn.transplant.hrsa.gov).
Relapseof theoriginal indication forHCT is a limitation that
can adversely affect the outcome of LT, but a previous history
of cancer does not automatically disqualify a patient for
considerationof LT. In2006, the International Society forHeart
and Lung Transplantation (ISHLT) published guidelines for the
selection of LTcandidates, based on retrospective registry data
and expert consensus opinion. These guidelines suggest that
absolute contraindications include malignancy within the
past 2 years, as well as any other end-organ failure (Table 3)
[37]. The appropriate time frame inwhich one can be deemed
free of recurrence is matter of expert consensus, although
there are reports suggesting that in patients with a history
of previous malignancy, the risk of recurrence is greatest
within the ﬁrst year and signiﬁcantly lower after 5 years [38].
Nearly all of our cases conformed to the 2006 ISHLT
guidelines proposing that LT is contraindicated in patients
who have had malignancy within the past 2 years [37]. Most
cases had much longer intervals between HCT and LT (me-
dian, 5 years), but in a few cases, the progression and severity
of the lung disease prompted LTearlier than 2 years fromHCT.
In an Austrian series reported by Vogl et al. [24], the median
time between HCT and LT was 18 months, with a range of
6 months to 120 months, likely reﬂecting the relatively early
onset of pulmonary GVHD at a median of 8.2 months after
HCT in this cohort. One patient died of a secondary malig-
nancy (myxoﬁbrosarcoma) at 24 months after LT.
In our series, only 1 patient experienced recurrence of the
original hematologic disease after LT, which she underwent
at 9.4 years after undergoing allogeneic HCT for chronic
myelogenous leukemia. The indication for LT was primary
pulmonary arterial hypertension thought to be unrelated to
the HCT. This patient lived for 7.3 years after LT, and died of
pulmonary infection and active chronic myelogenous leu-
kemia. The only other reported malignant complication after
LT was reported in a Scandinavian series, in which 1 of the
2 deaths was a patient who died with relapsed acute mye-
logenous leukemia at 2.1 years after allogeneic HCT and
1.1 years after bilateral LT [25].
Considerations in the Selection of LT Candidates
after HCT
Speciﬁc recommendations for the selection of LT candi-
dates after HCT must be extrapolated from our knowledge ofTable 3
Contraindications to LT (Summary of ISHLT 2006 Guidelines)
Absolute Relative
 Malignancy within last 2 years  Age >65 years
 Advanced dysfunction of other
organ system
 Critical condition
 Noncurable chronic infection  Poor functional status
 Chest wall deformity  Colonization with resistant
organisms
 Noncompliance  Body mass index >30
 Lack of social support  Severe osteoporosis
 Substance abuse  Mechanical ventilation
G.-S. Cheng et al. / Biol Blood Marrow Transplant 20 (2014) 1169e11751174common indications and the ISHLT generalized consensus
guidelines, as well as considerations speciﬁc to HCT survi-
vors. In addition to a history of malignancy or hematologic
disease, the HCT population is distinguished from con-
ventional LT candidates by late complications of GVHD and
ongoing systemic immunosuppression. The evaluation of
potential candidates for LT should include assessment and
consideration of extrapulmonary morbidities. In the HCT
population, hematologic cell populations, as well as cellular
and humoral immune function, should be evaluated. The
presence and activity of systemic GVHD manifestations and
treatment complications must be considered as well.
Malabsorption, nutritional compromise, hepatic dysfunction,
renal dysfunction, and esophageal disease pose additional
potential risks for LT. Signiﬁcant immunosuppression re-
quirements for control of GVHD suggest continued systemic
disease activity and may preclude LT.
Patient factors that likely improve the chances of a good
long-term outcome include young age, at least 2 years post-
HCT free of relapse from original hematologic malignancy,
and lack of other end-organ dysfunction or manifestations of
severe active cGVHD that require treatment with immuno-
suppressive agents.CONCLUSION
LT after HCT is a viable therapeutic option for patients
cured of their hematologic disease and whose only signiﬁ-
cant post-HCT morbidity is end-stage lung disease. Our case
series and review of the literature suggest that select patients
with a history of hematologic malignancy or disease treated
by HCT can have acceptable long-term outcomes after
LT. Ideal candidates should have a prolonged period of
malignancy-free survival after HCT, minimal extrathoracic
disease with minimal chronic manifestations of GVHD,
minimal immunosuppressive needs for GVHD treatment,
and normal engraftment and immune function. As the HCT
survivor population continues to grow, consensus guidelines
and a prospective international registry are necessary to
further reﬁne selection criteria for LT.ACKNOWLEDGMENTS
We thank Dr. Steve Pergam for his editorial comments
and Keira Oh for her assistance with manuscript preparation.
Financial disclosure: The authors have no ﬁnancial con-
ﬂicts to disclose.
Conﬂict of interest statement: There are no conﬂicts of
interest to report.REFERENCES
1. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allo-
geneic hematopoietic-cell transplantation. N Engl J Med. 2010;363:
2091-2101.
2. Solh M, Arat M, Cao Q, et al. Late-onset noninfectious pulmonary
complications in adult allogeneic hematopoietic cell transplant re-
cipients. Transplantation. 2011;91:798-803.
3. Au BK, Au MA, Chien JW. Bronchiolitis obliterans syndrome epidemi-
ology after allogeneic hematopoietic cell transplantation. Biol Blood
Marrow Transplant. 2011;17:1072-1078.
4. International Society for Heart and Lung Transplantation. International
Heart and Lung Transplant Registry. Available at: http://www.ishlt.org/
registries. Accessed October 15, 2013.
5. Calhoon JH, Levine S, Anzueto A, et al. Lung transplantation in a patient
with a prior bone marrow transplant. Chest. 1992;102:948.
6. Vigorito AC, Campregher PV, Storer BE, et al. Evaluation of NIH
consensus criteria for classiﬁcation of late acute and chronic GVHD.
Blood. 2009;114:702-708.
7. Gascoigne A, Corris P. Lung transplants in patients with prior bone
marrow transplants. Chest. 1994;105:327.8. Boas SR, Noyes BE, Kurland G, et al. Pediatric lung transplantation for
graft-versus-host disease following bone marrow transplantation.
Chest. 1994;105:1584-1586.
9. Svendsen UG, Aggestrup S, Heilmann C, et al. Transplantation of a lobe
of lung from mother to child following previous transplantation with
maternal bone marrow. Eur Resp J. 1995;8:334-337.
10. Svendsen UG, Aggestrup S, Heilmann C, et al. Transplantation of a
lobe of lung from mother to child following previous transplantation
with maternal bone marrow. J Heart Lung Transplant. 1999;18:
388-390.
11. Heath JA, Kurland G, Spray TL, et al. Lung transplantation after allo-
geneic marrow transplantation in pediatric patients: the Memorial
Sloan-Kettering experience. Transplantation. 2001;72:1986-1990.
12. Rabitsch W, Deviatko E, Keil F, et al. Successful lung transplantation for
bronchiolitis obliterans after allogeneic marrow transplantation.
Transplantation. 2001;71:1341-1343.
13. Pechet TV, de le Morena M, Mendeloff EN, et al. Lung transplantation in
children following treatment for malignancy. J Heart Lung Transplant.
2003;22:154-160.
14. Sano Y, Date H, Nagahiro I, et al. Living-donor lobar lung trans-
plantation for bronchiolitis obliterans after bone marrow trans-
plantation. Ann Thorac Surg. 2005;79:1051-1052.
15. Okumura H, Ohtake S, Ontachi Y, et al. Living-donor lobar lung trans-
plantation for broncho-bronchiolitis obliterans after allogeneic he-
matopoietic stem cell transplantation: does bronchiolitis obliterans
recur in transplanted lungs? Int J Hematol. 2007;86:369-373.
16. Shiraishi T, Hiratsuka M, Munakata M, et al. Living-donor single-lobe
lung transplantation for bronchiolitis obliterans in a 4-year-old boy.
J Thorac Cardiovasc Surg. 2007;134:1092-1093.
17. Au WY, Lie AK, Cheng VC, et al. Successful lung transplantation for
post-BMT bronchiolitis obliterans and lipoid pneumonia associated
with atypical mycobacterium and aspergillosis infection. J Heart Lung
Transplant. 2007;26:870-872.
18. Yamane M, Sano Y, Toyooka S, et al. T. Living-donor lobar lung trans-
plantation for pulmonary complications after hematopoietic stem cell
transplantation. Transplantation. 2008;86:1767-1770.
19. Oshima K, Kikuchi A, Mochizuki S, et al. Living-donor single-lobe lung
transplantation for bronchiolitis obliterans from mother to child
following previous allogeneic hematopoietic stem cell transplantation
from the same donor. Int J Hematol. 2009;90:540-542.
20. Redel-Montero J, Bujalance-Cabrera C, Vaquero-Barrios JM, et al. Lung
transplantation for bronchiolitis obliterans after allogeneic bone
marrow transplantation. Transplant Proc. 2010;42:3023-3025.
21. Whitson BA, Shelstad RC, Hertz MI, et al. Lung transplantation after
hematopoietic stem cell transplantation. Clin Transplant. 2012;26:
254-258.
22. Kim YR, Haam SJ, Park YG, et al. Lung transplantation for bronchiolitis
obliterans after allogeneic hematopoietic stem cell transplantation.
Yonsei Med J. 2012;53:1054-1057.
23. Yousef S, Benden C, Boyer D, et al. Lung transplantation in children
following bone marrow transplantation: a multi-center experience.
Pediatr Transplant. 2013;17:231-236.
24. Vogl UM, Nagayama K, Bojic M, et al. Lung transplantation for bronchio-
litis obliterans after allogeneic hematopoietic stem cell transplantation: a
single-center experience. Transplantation. 2013;95:623-628.
25. Holm AM, Riise GC, Hansson L, et al. Lung transplantation for bron-
chiolitis obliterans syndrome after allo-SCT. Bone Marrow Transplant.
2013;48:703-707.
26. Dudek AZ, Mahaseth H, Defor TE, Weisdorf DJ. Bronchiolitis oblit-
erans in chronic graft-versus-host disease: analysis of risk factors
and treatment outcomes. Biol Blood Marrow Transplant. 2003;9:
657-666.
27. Gratwohl A, Baldomero H, Gratwohl M, et al. Quantitative and quali-
tative differences in use and trends of hematopoietic stem cell trans-
plantation: a Global Observational Study. Haematologica. 2013;98:
1282-1290.
28. Pasquini MC, Wang Z. Current use and outcome of hematopoietic stem
cell transplantation: CIBMTR summary slides. Available at: http://
www.cibmtr.org. Accessed January 30, 2014.
29. Alousi AM, Bolanos-Meade J, Lee SJ. Graft-versus-host disease: state of
the science. Biol Blood Marrow Transplant. 2013;19:S102-S108.
30. Scientiﬁc Registry of Transplant Recipients. 2011 annual data tables.
Available at: http://www.srtr.org/annual_Reports/2011/data_tables_
section12.aspx. Accessed January 31, 2014.
31. Valapour M, Paulson K, Smith JM, et al. OPTN/SRTR 2011 annual data
report: lung. Am J Transplant. 2013;13(Suppl 1):149-177.
32. Weigt SS, Derhovanessian A, Wallace WD, et al. Bronchiolitis obliterans
syndrome: the Achilles’ heel of lung transplantation. Semin Respir Crit
Care Med. 2013;34:336-351.
33. Benden C, Edwards LB, Kucheryavaya AV, et al. The Registry of the
International Society for Heart and Lung Transplantation: Sixteenth
Ofﬁcial Pediatric Lung and Heart-Lung Transplantation Reporte2013;
Focus Theme: Age. J Heart Lung Transplant. 2013;32:989-997.
34. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the
International Society for Heart and Lung Transplantation: 29th adult
G.-S. Cheng et al. / Biol Blood Marrow Transplant 20 (2014) 1169e1175 1175lung and heart-lung transplant report, 2012. J Heart Lung Transplant.
2012;31:1073-1086.
35. Sayegh MH, Fine NA, Smith JL, et al. Immunologic tolerance to renal
allografts after bone marrow transplants from the same donors. Ann
Intern Med. 1991;114:954-955.
36. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and
chimerism after renal and hematopoietic-cell transplantation. N Engl J
Med. 2008;358:362-368.37. Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the
selection of lung transplant candidates: 2006 update. A consensus
report from the Pulmonary Scientiﬁc Council of the International
Society for Heart and Lung Transplantation. J Heart Lung Transplant.
2006;25:745-755.
38. Sigurdardottir V, Bjortuft O, Eiskjaer H, et al. Long-term follow-up of
lung and heart transplant recipients with pre-transplant malignancies.
J Heart Lung Transplant. 2012;31:1276-1280.
